On October 14, 2015 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that it has received a US$5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licencing agreement (Press release, Innate Pharma, OCT 14, 2015, View Source [SID:1234507714]). Schedule your 30 min Free 1stOncology Demo! This payment was triggered by the dosing of a first patient in a Phase II trial of lirilumab in combination with rituximab in patients with relapsed/ refractory or high-risk untreated Chronic Lymphocytic Leukemia.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hervé Brailly, CEO and co-founder of Innate Pharma, said: "This milestone marks the start of a new Phase II trial of lirilumab in hemato-oncology outside of Acute Meloid Leukemia. We are pleased with the broad clinical program for lirilumab, and expect that results will begin to be delivered in 2016".
In total, 6 trials are currently being performed with lirilumab, testing a range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, checkpoint inhibitors and chemotherapy.